20.14
+3.07%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kuros Biosciences
Its shares trade on SIX under the ticker KURN.SW. It has been listed since 29 October 2002. In the fiscal year to 31 December 2025, it reported revenue of $121.3m and net income of $2.1m. At that date it held total assets of $87.1m and shareholders' equity of $54.4m.
Kuros Biosciences Ltd. engages in the e discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Oct 2002
- Employees
- 42
- Website
- kuros.ch ↗
Leadership
Pay as last reported
- Prof. Dr. Clemens Van BlitterswijkNon-Executive Chairman of the Board of DirectorsCHF 153,500
- Mr. Chris FairChief Executive Officer, Executive Director, Member of the Executive Board, since 2021CHF 3.9m
- Mr. Daniel GeigerChief Financial Officer, Member of the Executive Board
- Mr. Sjoerd MustersChief Operating Officer, Member of the Executive Board
- Dr. Joost de BruijnExecutive Director, Member of the Executive Board, President of Innovation and Strategy, since 2017CHF 873,700
- Ms. Kimberley EltingNon-Executive Member of the Board of Directors
- Mr. Oliver WalkerNon-Executive Member of the Board of DirectorsCHF 129,800
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 44
- Social
- 43
- Governance
- 35
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kuros Biosciences AG has several strengths that contribute to its overall success. Firstly, the company has a strong and experienced management team that possesses extensive knowledge in the field of biosciences. This expertise enables them to make informed decisions and effectively steer the company towards its goals. Secondly, Kuros Biosciences AG has a robust portfolio of innovative products and technologies. These offerings address unmet needs in the healthcare industry and have the potential to revolutionize patient care. The company's commitment to research and development ensures a constant stream of new and improved products. Additionally, the company has established strong partnerships with key stakeholders in the industry. These collaborations provide access to additional resources, expertise, and potentially lucrative markets. The strategic positioning of the business allows Kuros Biosciences AG to effectively compete and differentiate itself from competitors. Lastly, the company has a solid financial position with consistent revenue growth. This stability enables Kuros Biosciences AG to invest in further research and development, expand its operations, and capitalize on emerging opportunities in the market.
Weaknesses
- While Kuros Biosciences AG has significant strengths, it also faces certain weaknesses that could hinder its progress. One weakness is the company's dependence on a limited number of products. This concentration increases the risk associated with these offerings and leaves the company vulnerable to any disruptions in their manufacturing or adoption. Another weakness lies in the company's limited geographic presence. Kuros Biosciences AG operates mainly in specific regions, which narrows its potential market and limits its growth opportunities. Expanding into new territories would require significant investments and may involve regulatory complexities. Furthermore, the company faces intense competition from well-established players in the biosciences industry. This competition puts pressure on Kuros Biosciences AG to continuously innovate and differentiate its products from rivals. Failure to do so may result in a loss of market share and decreased profitability. Lastly, the company's lack of brand recognition compared to larger competitors poses a challenge in attracting and retaining customers. Building brand equity is a time-consuming and costly process that requires significant investments in marketing and advertising.
Opportunities
- Kuros Biosciences AG has several opportunities for growth and expansion. Firstly, advancements in technology and research provide opportunities for the development of new products and therapies. Kuros Biosciences AG can leverage its expertise to capitalize on these advancements and introduce innovative solutions to the market. Secondly, increasing healthcare spending globally presents a favorable market environment for Kuros Biosciences AG. The growing demand for improved healthcare services and treatments creates opportunities for the company to expand its customer base and increase revenue. Additionally, partnerships and collaborations with academic institutions and research organizations offer opportunities for knowledge exchange, access to novel technologies, and joint development of products. These collaborations can enhance Kuros Biosciences AG's research capabilities and further differentiate its offerings. Lastly, expanding into new geographical markets can help Kuros Biosciences AG diversify its revenue streams and reduce dependence on specific regions. Exploring emerging markets and strategic alliances with local partners can accelerate the company's growth trajectory.
Threats
- Kuros Biosciences AG faces several threats that could impact its business operations. One significant threat is the stringent regulatory environment governing the biosciences industry. Compliance with complex regulations and obtaining necessary approvals can be time-consuming and costly, potentially delaying product launches. Other threats include rapidly evolving technological advancements that may render existing products obsolete. Kuros Biosciences AG needs to stay at the forefront of innovation and adapt quickly to changing market dynamics to remain competitive. Economic fluctuations and financial instability can also pose challenges to the company. Uncertain economic conditions may limit healthcare budgets and reduce demand for certain products and services. Lastly, the threat of intellectual property infringement and competition from generic alternatives remains a concern. Protecting intellectual property through patents and maintaining a strong competitive advantage is crucial for Kuros Biosciences AG to retain its market position and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.